Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Cyclo-oxygenase 2 inhibitors, NSAIDs, and the risk of cardiovascular events

Nature Clinical Practice Rheumatology volume 2, pages 586–587 (2006)Cite this article

Access through your institution
Buy or subscribe

boxed-textKearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302–1308

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Solomon SD et al. (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028–1035

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine at the Brigham and Women's Hospital at Harvard Medical School, Boston, MA, USA

    Daniel H Solomon

Authors
  1. Daniel H Solomon
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Daniel H Solomon.

Ethics declarations

Competing interests

Dr Solomon has received research grants from Merck and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solomon, D. Cyclo-oxygenase 2 inhibitors, NSAIDs, and the risk of cardiovascular events. Nat Rev Rheumatol 2, 586–587 (2006). https://doi.org/10.1038/ncprheum0341

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncprheum0341

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing